 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| BICX Looking Strong on Good Volume Up as Much as 25% Today |
|
 Hot Stock to Watch |
Company: BioCorRx Inc. (OTCQB: BICX)
|
Last:
Price: 0.07
Change (%): + 0.0039 (5.90)
Volume: 195,537 |
 |
BioCorRx, Inc. and Start Fresh Featured on MSNBC, SAMHSA and NIAAA Endorse Medication for Treatment of Alcohol Abuse Disorders
Los Angeles, April 28, 2015 (GLOBE NEWSWIRE) - BioCorRx, Inc. (BICX) announces MSNBC segment featuring Brady Granier, COO and interim CEO, alongside Start Fresh Program and Growing Pains alum, Jeremy Miller. The two were interviewed by Tamron Hall of NewsNation to discuss Jeremy’s success with the Start Fresh Program, a medication-assisted treatment program developed by BioCorRx that is used to treat alcohol and opioid addiction. The MSNBC segment originally aired on April 21, 2015 and can be viewed online here.
This television appearance followed a recent endorsement of medication-assisted treatment (MAT) for alcohol addiction by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). According to an article found here from Healio.com earlier this month, the groups collaborated on assembling a panel of experts to review data on the efficacy of treatment protocols that use medication in the treatment of alcoholism. The panel’s findings showed drugs such as Naltrexone, the FDA approved pharmaceutical used in the specially formulated implant that is part of the Start Fresh Program, to be effective in the treatment of alcohol abuse as well as managing relapse.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
